

HCC MELD Exception Form

Date: _____

Outside Imaging

Hepatologist/Surgeon: _____

Radiologist: _____

Patient's Name: _____

MR#: _____

DOB: _____

Diagnosis: _____

_____ Baseline AFP _____ Lowest AFP _____ Current AFP _____

CT Chest prior to initial application: _____ Most recent CT Chest: _____

Bridging Therapies: _____

SUMMARY REPORT				DATE:
<input type="checkbox"/> Initial Exam	<input type="checkbox"/> MRI <input type="checkbox"/> CT			
<input type="checkbox"/> Follow-up Exam	<input type="checkbox"/> MRI <input type="checkbox"/> CT			
FINDINGS				
Total number of OPTN class 5 lesions (HCC):				
Enhancement Features	Nodule OPTN Class [5A-g]	Nodule Size [cm]	Location	
1. 1 2 3 4				
2. 1 2 3 4				
3. 1 2 3 4				
4. 1 2 3 4				
1. Nonrim arterial phase hyper-enhancement				
2. Nonperipheral washout				
3. Enhancing capsule				
4. Threshold growth defined as size increase of a mass by $\geq 50\%$ in ≤ 180 days on MRI or CT				

Comments: _____

Signature: _____

9.5.1.i Initial Assessment and Requirements for HCC Exception Requests

Prior to applying for a standardized MELD or PELD exception, the candidate must undergo a thorough assessment that includes *all* of the following:

1. An evaluation of the number and size of lesions before local-regional therapy that meet Class 5 criteria using a dynamic contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI)
2. A CT of the chest to rule out metastatic disease. This is only required prior to applying for an initial exception. A CT of the chest is not required for exception extensions.
3. A CT or MRI to rule out any other sites of extrahepatic spread or macrovascular involvement
4. An indication that the candidate is not eligible for resection
5. An indication whether the candidate has undergone local-regional therapy
6. The candidate's alpha-fetoprotein (AFP) level

**Table 9-9: Classification System for Lesions
Seen on Imaging of Livers**

Class	Description
NC – Not Categorizable	Incomplete or technically inadequate study due to image degradation or omission
5A	Must meet <i>all</i> of the following: 1. Maximum diameter of at least 1 cm and less than 2 cm, as measured on late arterial or portal phase images 2. Nonrim arterial phase hyper-enhancement 3. <i>Either</i> of the following: • Non-peripheral washout • Biopsy
5A-g	Must meet <i>all</i> of the following: 1. Maximum diameter of at least 1 cm and less than 2 cm, as measured on late arterial or portal phase images 2. Nonrim arterial phase hyper-enhancement 3. Threshold growth defined as size increase of a mass by $\geq 50\%$ in ≤ 180 days on MRI or CT
5B	Must meet <i>all</i> of the following: 1. Maximum diameter of at least 2 cm and less than or equal to 5 cm, as measured on late arterial or portal phase images 2. Nonrim arterial phase hyper-enhancement 3. <i>One</i> of the following: a. Nonperipheral washout b. Enhancing capsule c. Threshold growth defined as size increase of a mass by $\geq 50\%$ in ≤ 180 days on MRI or CT d. Biopsy
5T	Any Class 5A, 5A-g, 5B lesion that was automatically approved upon initial request or extension and has subsequently been treated by locoregional therapy

OPTN Policies Effective Date: 4/2/2024